SCHEMBL6643979

SCHEMBL6643979

Cc1ccc(-c2ccccc2C(=O)Nc2ccc(NCCn3nccc3N)nc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR2 O43614 2/20 0.41
KMT2A Q03164 2/20 0.39
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
OPRL1 P41146 1/20 0.38
AXL P30530 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
RAB9A P51151 3/20 0.38
ALDH1A1 P00352 3/20 0.38
NPC1 O15118 2/20 0.38
MAPK1 P28482 1/20 0.38
AVPR2 P30518 1/20 0.38
LMNA P02545 1/20 0.38
MEN1 O00255 1/20 0.37
CHRNB2 P17787 1/20 0.37
CHRNB4 P30926 1/20 0.37
CHRNA3 P32297 1/20 0.37
CHRNA4 P43681 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6649191 0.89 KMT2A (0.45) KMT2AHSD17B10SMN1; SMN2OPRL1L3MBTL1
SCHEMBL6645771 0.81 HCRTR2 (0.38) HCRTR2MAPTNPSR1HSD17B10SMN1; SMN2
SCHEMBL6642272 0.73 SMO (0.43) MAPTSMN1; SMN2L3MBTL1RAB9AALDH1A1
SCHEMBL6643444 0.73 SCN10A (0.40) ALDH1A1
SCHEMBL6644841 0.72 ALDH1A1 (0.46) KMT2AHSD17B10SMN1; SMN2L3MBTL1RAB9A
SCHEMBL6646726 0.70 PTGS1 (0.46) MAPTSMN1; SMN2ALDH1A1LMNAKDM4E
SCHEMBL7996540 0.70 MTTP (0.53)
SCHEMBL6644574 0.69 KDR (0.46) KMT2AMAPTHSD17B10SMN1; SMN2L3MBTL1
SCHEMBL6644772 0.69 NPC1 (0.40) KMT2AMAPTNPSR1HSD17B10SMN1; SMN2
SCHEMBL6644423 0.69 NPC1 (0.39) KMT2AMAPTHSD17B10RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR HCRTR2 234/4885KMT2A 916/4885MAPT 4101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.